slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 78,901-78,930
Pages 3,679
Rows per page 30
Component
78,901-78,930 of 110,355
03
The slide uses a grid layout to present four brand profiles, each with a background image, logo, and descriptive text.a.k.a. Brands | Investor Presentation Deck | 21 slides · a.k.a. Brands
Pitch deck Investor relations 1 hit
14
Includes brand logo, retail store photo, and lifestyle imagery.a.k.a. Brands | Investor Presentation Deck | 21 slides · a.k.a. Brands
Pitch deck Investor relations 1 hit
15
Slide provides a brand profile for Petal and Pup.a.k.a. Brands | Investor Presentation Deck | 21 slides · a.k.a. Brands
Pitch deck Investor relations 1 hit
05
The slide uses a combination of bar charts for repurchases/dividends and a line chart for share counts.BlackRock | Results Presentation Deck | 16 slides · BlackRock
Deck Investor relations Beat · What IsLoop · Mece Breakdown1 hit
06
Data sourced from Bloomberg; includes a specific footnote regarding the BLK Equity Index calculation methodology.BlackRock | Results Presentation Deck | 16 slides · BlackRock
Deck Investor relations Beat · What Could BeLoop · Mece Breakdown1 hit
11
The chart uses a bridge/waterfall format to illustrate the $1.701 billion increase in revenue.BlackRock | Results Presentation Deck | 16 slides · BlackRock
Deck Investor relations Beat · New Bliss1 hit
07
Includes a break in the Q4 23 bar and specific footnotes regarding non-recurring tax adjustments and Farfetch losses.Coupang | Results Presentation Deck | 25 slides · Coupang
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
Includes specific callouts for Farfetch impact and tax-related adjustments.Coupang | Results Presentation Deck | 25 slides · Coupang
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
10
The slide highlights the impact of an FLC accounting change and the exclusion of Farfetch on the reported metrics.Coupang | Results Presentation Deck | 25 slides · Coupang
Conference presentation Investor relations Beat · Financials1 hit
09
The slide uses a 3x2 matrix structure to contrast clinical efficacy, market opportunity, and current treatment limitations.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
13
The slide uses a timeline framework to illustrate the stacking of IP protections over time.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
15
The slide outlines the clinical development strategy for a drug candidate, emphasizing continuity from Phase 2b to Phase 3.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
17
The slide uses a list-based framework to map clinical outcomes to target product profile attributes.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
18
The slide outlines two distinct study protocols with specific sample sizes and dosing regimens, including a primary endpoint at week 12.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
19
Includes study timeline, randomization, entry criteria, and endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
20
Shows a process flow between follow-up observation and potential treatment based on clinical criteria.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
24
The chart displays LS Mean Change from baseline across multiple dose groups (25, 50, 100, 200 ug) versus placebo.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
25
The slide outlines a clinical trial protocol with a primary endpoint at week 6 and a 40-week extension phase.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
26
Includes study timeline, randomization details, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
28
The slide emphasizes regulatory alignment and standard clinical trial methodology.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
29
Includes study arms, dosing, follow-up timeline, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
30
Uses a comparison table to define what is and is not part of the patient journey.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
32
The table displays mean age, sex distribution, race, and baseline HAM-A and CGI-S scores for n=194 participants.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
33
The chart highlights the efficacy of the 100ug dose group specifically in the callout box.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
34
Data compares Placebo, 25ug, 50ug, 100ug, and 200ug doses.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
35
MCP-Mod is a statistical methodology for dose-response modeling.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
36
The chart shows a clear separation between placebo and treatment groups across time points.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
37
The slide uses a structured list format to present safety outcomes.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
38
The table highlights that while adverse events occur, they are largely concentrated on the dosing day, suggesting a favorable tolerability profile.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
41
The slide uses a bar chart to demonstrate efficacy in an animal model and an icon grid to summarize clinical benefits.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit